Literature DB >> 22459735

Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape.

Nora Martel1, Laurent Cotte, Mary-Anne Trabaud, Christian Trepo, Fabien Zoulim, Selma A Gomes, Alan Kay.   

Abstract

We describe a patient infected with human immunodeficiency virus who possessed a serological profile suggesting a previous cleared acute hepatitis B virus (HBV) infection, including high levels of antibodies against HBV surface antigen (anti-HBs). Following the administration of inhaled glucocorticosteroids combined with protease inhibitor-based antiretroviral treatment, the patient developed an unexpected severe acute hepatitis despite persistence of anti-HBs. A genotype A2 strain emerged with 2 major mutations in the S gene, sK122R and sD144E. Molecular and biological analyses strongly suggested reactivation of a latent HBV infection. The importance and the molecular basis of these 2 epitopes in immune-escape mechanisms and host-virus interactions are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459735     DOI: 10.1093/infdis/jis268

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Co-morbid infections in Hansen's disease patients in the United States: considerations for treatment.

Authors:  Madeline Bilodeau; Stephanie Burns; John Gawoski; Samuel Moschella; Winnie Ooi
Journal:  Am J Trop Med Hyg       Date:  2013-08-26       Impact factor: 2.345

Review 2.  Genetic variation of hepatitis B virus and its significance for pathogenesis.

Authors:  Zhen-Hua Zhang; Chun-Chen Wu; Xin-Wen Chen; Xu Li; Jun Li; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).

Authors:  Jason T Blackard; Kenneth E Sherman
Journal:  Rev Med Virol       Date:  2018-05-15       Impact factor: 6.989

4.  Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-Hepatitis B core antibodies.

Authors:  Rongjuan Pei; Sebastian Grund; Jens Verheyen; Stefan Esser; Xinwen Chen; Mengji Lu
Journal:  Virol J       Date:  2014-01-21       Impact factor: 4.099

5.  Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.

Authors:  Luna Colagrossi; Lucas E Hermans; Romina Salpini; Domenico Di Carlo; Suzan D Pas; Marta Alvarez; Ziv Ben-Ari; Greet Boland; Bianca Bruzzone; Nicola Coppola; Carole Seguin-Devaux; Tomasz Dyda; Federico Garcia; Rolf Kaiser; Sukran Köse; Henrik Krarup; Ivana Lazarevic; Maja M Lunar; Sarah Maylin; Valeria Micheli; Orna Mor; Simona Paraschiv; Dimitros Paraskevis; Mario Poljak; Elisabeth Puchhammer-Stöckl; François Simon; Maja Stanojevic; Kathrine Stene-Johansen; Nijaz Tihic; Pascale Trimoulet; Jens Verheyen; Adriana Vince; Snjezana Zidovec Lepej; Nina Weis; Tülay Yalcinkaya; Charles A B Boucher; Annemarie M J Wensing; Carlo F Perno; Valentina Svicher
Journal:  BMC Infect Dis       Date:  2018-06-01       Impact factor: 3.090

Review 6.  Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies.

Authors:  Jun Inoue; Takuya Nakamura; Atsushi Masamune
Journal:  Viruses       Date:  2019-05-19       Impact factor: 5.048

Review 7.  Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression.

Authors:  Ivana Lazarevic; Ana Banko; Danijela Miljanovic; Maja Cupic
Journal:  Viruses       Date:  2019-08-24       Impact factor: 5.048

Review 8.  New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts.

Authors:  Valentina Svicher; Romina Salpini; Vincenzo Malagnino; Lorenzo Piermatteo; Mohammad Alkhatib; Carlotta Cerva; Loredana Sarmati
Journal:  Viruses       Date:  2019-08-25       Impact factor: 5.048

Review 9.  A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.

Authors:  Renato Ferreira-da-Silva; Inês Ribeiro-Vaz; Manuela Morato; Jorge Junqueira Polónia
Journal:  Eur J Clin Invest       Date:  2022-02-27       Impact factor: 5.722

10.  Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.

Authors:  Adam Abdullahi; Olga Mafotsing Fopoussi; Judith Torimiro; Mark Atkins; Charles Kouanfack; Anna Maria Geretti
Journal:  Open Forum Infect Dis       Date:  2018-10-05       Impact factor: 3.835

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.